KT-621, an Oral STAT6 Degrader, in Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Asthma or Allergic Rhinitis: Safety and Evidence of Clinical Activity Across Type 2 Inflammatory Diseases in a Phase 1b Trial
September 8, 2026
KT-621, an Oral STAT6 Degrader, in Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Asthma or Allergic Rhinitis: Safety and Evidence of Clinical Activity Across Type 2 Inflammatory Diseases in a Phase 1b Trial
European Respiratory Society (ERS) 2026
Authors: Michael B. Feldman, Jared Gollob, Joyoti Dey, Kelvin Shi, Sagar Agarwal, Neil Graham, Nello Mainolfi
Area of Focus
Immunology
Programs
STAT6 (KT-621)
Indications
Atopic Dermatitis (AD)
Development Stage
Clinical Data
Share
